

STATE OF NEW YORK

6927--A

2025-2026 Regular Sessions

IN ASSEMBLY

March 18, 2025

Introduced by M. of A. SIMONE, TAPIA, GONZALEZ-ROJAS, REYES, SHIMSKY, GLICK, SCHIAVONI, LUNSFORD, ROMERO, MEEKS, BRONSON, SEAWRIGHT, HEVESI, SIMON, ROSENTHAL, RAGA, LEE, WRIGHT, LEVENBERG, KELLES -- read once and referred to the Committee on Higher Education -- recommitted to the Committee on Higher Education in accordance with Assembly Rule 3, sec. 2 -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the education law and the public health law, in relation to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy for treatment of gender dysphoria

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

1 Section 1. Paragraph b-1 of subdivision 1 of section 6807 of the
2 education law, as amended by chapter 108 of the laws of 2025, is amended
3 to read as follows:

4 b-1. Notwithstanding paragraph b of this [~~section~~] subdivision, the
5 prescription label for mifepristone [~~ex~~], misoprostol, gonadotropin-re-
6 leasing hormone agonists, pubertal suppressants, anabolic steroids,
7 alpha reductase inhibitors, progestins, or drug classes for hormone
8 replacement therapy for treatment of gender dysphoria, may include the
9 name or address of the dispensing health care practice instead of the
10 name of the dispenser.

11 § 2. Subdivision 1-a of section 6810 of the education law, as amended
12 by chapter 108 of the laws of 2025, is amended to read as follows:

13 1-a. Notwithstanding subdivision one of this section, at the
14 prescriber's request, the prescription label for mifepristone [~~ex~~],
15 misoprostol, gonadotropin-releasing hormone agonists, pubertal suppres-
16 sants, anabolic steroids, alpha reductase inhibitors, progestins, or
17 drug classes for hormone replacement therapy for treatment of gender

EXPLANATION--Matter in italics (underscored) is new; matter in brackets [~~-~~] is old law to be omitted.

LBD10852-03-6

1 dysphoria, shall include the name or address of the prescribing health
2 care practice instead of the name of the prescriber.
3 § 3. Section 280-d of the public health law, as added by chapter 108
4 of the laws of 2025, is amended to read as follows:
5 § 280-d. Patient notification of prescription label change. A health
6 care prescriber shall inform the patient if such prescriber has included
7 or has requested to include the name or address of the prescribing
8 health care practice instead of the name of such prescriber on the
9 prescription label when prescribing mifepristone [~~ex~~], misoprostol,
10 gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic
11 steroids, alpha reductase inhibitors, progestins, or drug classes for
12 hormone replacement therapy for treatment of gender dysphoria.
13 § 4. This act shall take effect immediately.